JINHAI MED TECH (02225) surged more than 18% in morning trading on Monday, reflecting robust investor enthusiasm. As of the time of writing, the stock was up 15.60% to HK$4.855, with turnover reaching HK$57.868 million.

On the news front, the Shenzhen Stock Exchange announced on September 7 that, in accordance with the relevant provisions of the Shenzhen-Hong Kong Stock Connect Implementation Rules, the list of eligible securities for the Stock Connect program has been adjusted, effective September 7. Notably, JINHAI MED TECH has been added to the list. This inclusion is anticipated to broaden the company's shareholder base, attract long-term institutional investors, and enhance the liquidity of its share trading.

It is worth highlighting that in the first half of the year, JINHAI MED TECH achieved a significant optimization in its revenue mix, with its strategic focus successfully shifting from traditional labor services to the high value-added medical device sector. Revenue derived from minimally invasive surgical solutions, medical products, and related service fees has climbed to 74.73% of total revenue, solidifying its position as the company's new primary pillar of income.

Following robust growth in medical device sales revenue in 2025, the business segment saw a year-on-year surge of 301.5% in the first half of 2026, reaching SGD 25.427 million. This performance underscores the company's substantial and sustainable growth momentum moving forward.